OraSure Technologies Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by OraSure Technologies, Inc. on November 21, 2013. The filing discloses two material definitive agreements entered into on November 20 and November 21, 2013, regarding the company's oral fluid drugs of abuse testing portfolio.
Key Financial Metrics and Agreements
- Settlement Payment: The Company received an initial payment of $8.3 million from Roche Diagnostics upon termination of their collaboration.
- Transitional Supply: Roche agreed to supply five FDA 510(k) cleared assays to OraSure on a transitional basis for up to five years.
- Contingent Payments: OraSure may receive additional payments from Roche if the supply obligation is terminated prior to the end of the five-year period.
- New Partnership: An agreement was signed with Thermo Fisher Scientific to develop and supply up to 12 homogenous fully automated oral fluid drugs of abuse assays.
Material Changes
The filing marks a strategic shift in OraSure's drug testing operations:
- Termination of Roche Collaboration: The development and commercialization collaboration for fully-automated high throughput oral fluid drugs of abuse assays with Roche has been terminated.
- Strategic Replacement: OraSure has immediately pivoted to a new agreement with Thermo Fisher Scientific to develop similar assays compatible with the Company's Intercept oral fluid specimen collection device.
Outlook, Risks, and Management Commentary
Management has secured a transitional supply of existing assays from Roche while pursuing new development with Thermo Fisher. The commercialization of the new assays with Thermo Fisher is subject to the completion of development activities and the receipt of applicable regulatory approvals. The Company retains the right to purchase and resell these new assays in the U.S. and certain foreign countries.
Key Facts for Investor Verification
- Verify the total potential value of the settlement agreement, including the $8.3 million initial payment and any contingent future payments from Roche.
- Confirm the timeline for the completion of development activities and regulatory approvals required for the Thermo Fisher Scientific assays.
- Assess the impact of the Roche termination on the Company's current revenue stream from the five transitional assays.
- Review the specific terms regarding the Company's right to terminate the transitional supply from Roche early.